Drizalma Sprinkle Patent Expiration

Drizalma Sprinkle is a drug owned by Sun Pharmaceutical Industries Ltd. It is protected by 4 US drug patents filed from 2019 to 2022 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 13, 2037. Details of Drizalma Sprinkle's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9839626 Duloxetine sprinkles
Apr, 2037

(12 years from now)

Active
US10959982 Duloxetine sprinkles
Apr, 2037

(12 years from now)

Active
US11202772 Duloxetine sprinkles
Apr, 2037

(12 years from now)

Active
US10413525 Duloxetine sprinkles
Apr, 2037

(12 years from now)

Active


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Drizalma Sprinkle's patents.

Given below is the list of recent legal activities going on the following patents of Drizalma Sprinkle.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 4th Year, Large Entity 17 Mar, 2023 US10413525
Mail O.P. Petition Decision 26 Apr, 2022 US11202772
Email Notification 26 Apr, 2022 US11202772
Electronic Review 26 Apr, 2022 US11202772
Mail-Petition Decision - Granted 22 Apr, 2022 US11202772
Petition Decision - Granted 21 Apr, 2022 US11202772
O.P. Petition Decision 19 Apr, 2022 US11202772
Petition Entered 11 Apr, 2022 US11202772
Electronic Review 11 Mar, 2022 US11202772
Email Notification 11 Mar, 2022 US11202772

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Drizalma Sprinkle is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Drizalma Sprinkle's family patents as well as insights into ongoing legal events on those patents.

Drizalma Sprinkle's Family Patents

Drizalma Sprinkle has patent protection in a total of 3 countries. It has a significant patent presence in the US with 75.0% of its patents being US patents. Click below to unlock the full patent family tree for Drizalma Sprinkle.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Drizalma Sprinkle's generic launch date based on the expiry of its last outstanding patent is estimated to be Apr 13, 2037 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Drizalma Sprinkle Generics:

Duloxetine Hydrochloride is the generic name for the brand Drizalma Sprinkle. 23 different companies have already filed for the generic of Drizalma Sprinkle, with Breckenridge having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Drizalma Sprinkle's generic

Alternative Brands for Drizalma Sprinkle

There are several other brand drugs using the same active ingredient (Duloxetine Hydrochloride) as Drizalma Sprinkle. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name
Lilly
Cymbalta


Apart from brand drugs containing the same ingredient, some generics have also been filed for Duloxetine Hydrochloride, Drizalma Sprinkle's active ingredient. Check the complete list of approved generic manufacturers for Drizalma Sprinkle





About Drizalma Sprinkle

Drizalma Sprinkle is a drug owned by Sun Pharmaceutical Industries Ltd. Drizalma Sprinkle uses Duloxetine Hydrochloride as an active ingredient. Drizalma Sprinkle was launched by Sun Pharm in 2019.

Approval Date:

Drizalma Sprinkle was approved by FDA for market use on 19 July, 2019.

Active Ingredient:

Drizalma Sprinkle uses Duloxetine Hydrochloride as the active ingredient. Check out other Drugs and Companies using Duloxetine Hydrochloride ingredient

Dosage:

Drizalma Sprinkle is available in capsule, delayed rel pellets form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
EQ 20MG BASE CAPSULE, DELAYED REL PELLETS Prescription ORAL
EQ 60MG BASE CAPSULE, DELAYED REL PELLETS Prescription ORAL
EQ 40MG BASE CAPSULE, DELAYED REL PELLETS Prescription ORAL
EQ 30MG BASE CAPSULE, DELAYED REL PELLETS Prescription ORAL